Concept of disease in geriatric psychiatry

American Journal of Geriatric Psychiatry

Volumn 15, Issue 1, 2007, Pages 1-11

  Krishnan, K Ranga Rama ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Dementia; Disease; Vascular

Indexed keywords

AGED; ARTICLE; CLINICAL FEATURE; DEMENTIA; GENE MUTATION; GERONTOPSYCHIATRY; HUMAN; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NOMENCLATURE; PATHOGENESIS; PSYCHIATRIC DIAGNOSIS;

EID: 33846225203     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000224600.37387.4b     Document Type: Article

References (101)

1. Krishnan KR: Psychiatric disease in the genomic era: rational approach. Mol Psychiatry 2005; 11:978-984
2. Meier A: The research diagnostic criteria: historical background, development, validity, and reliability. Can J Psychiatry 1979; 24:167-178
3. Singerman B, Stoltzman RK, Robins LN, et al: Diagnostic concordance between DSM-III, Feighner, and RDC. J Clin Psychiatry 1981; 42:422-426
4. Temple LK, McLeod RS, Gallinger S, et al: Essays on science and society. Defining disease in the genomics era. Science 2001; 293:807-808
5. Boorse C: On the distinction between disease and illness. Philos Public Aff 1975; 5:49-68
6. Kendell RE: The distinction between personality disorder and mental illness. Br J Psychiatry 2002; 180:110-115
7. Scadding JG: Diagnosis: the clinician and the computer. Lancet 1967; 2:877-882
8. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association Press, 1994
9. Robins E, Guze SB: Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970; 126:983-987
10. Kendell RE: Five criteria for an improved taxonomy of mental disorders, in Defining Psychopathology in the 21st Century: DSM-V and Beyond. Edited by Heizer JE, Hudziak J. Washington, DC, American Psychiatric Association, 2002, pp 3-18
11. Kendell RE, Gourlay J: The clinical distinction between psychotic and neurotic depression. Br J Psychiatry 1970; 117:257-260
12. Kendell RE, Gourlay J: The clinical distinction between the affective psychoses and schizophrenia. Br J Psychiatry 1970; 117:261-266
13. Kendell RE, Brockington IF: The identification of disease entities and the relationship between schizophrenic and affective psychoses. Br J Psychiatry 1980; 137:324-331
14. Bradley W, Orgogozo JM, Van Drimmelen J, et al (eds.): Application of the International Classification of Diseases to Neurology, 2nd ed. Geneva, World Health Organization, 1997, p 574
15. Lopez O, Kuller LH, Fitzpatrick A, et al: Evaluation of dementia in the Cardiovascular Health Study. Neuroepidemiology 2003; 22:1-12
16. Roman GC, Sachdev P, Royall DR, et al: Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004; 226:81-87
17. Ancolio K, Dumanchin C, Barelli H, et al: Unusual phenotypic alteration of beta amyloid precursor protein (beta-APP) maturation by a new val715-to-met beta-APP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci U S A 1999; 96:4119-4124
18. Bakker E, van Broeckhoven C, Haan J, et al: DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type). Am J Hum Genet 1991; 49:518-521
19. Balbin M, Abrahamson M, Gustafson L, et al: A novel mutation in the beta-protein coding region of the amyloid beta-protein precursor (APP) gene. Hum Genet 1992; 89:580-582
20. Campion D, Dumanchin C, Hannequin D, et al: Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65:664-670
21. Carter DA, Desmarais E, Bellis M, et al: More missense in amyloid gene [Letter]. Nat Genet 1992; 2:255-256
22. Chartier-Harlin MC, Crawford F, Houlden H, et al: Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353:844-846
23. Cras P, van Harskamp F, Hendriks L, et al: Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692ala-gly mutation. Acta Neuropathol 1998; 96:253-260
24. De Jonghe C, Zehr C, Yager D, et al: Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol Dis 1998; 5:281-286
25. Di Luca M, Pastorino L, Bianchetti A, et al: Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 1998; 55:1195-1200
26. Eckman CB, Mehta ND, Crook R, et al: A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A-beta-42(43). Hum Mol Genet 1997; 6:2087-2089
27. Edwards-Lee T, Ringman JM, Chung J, et al: An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 2005; 64:377-379
28. Farlow M, Murrell J, Ghetti B, et al: Clinical characteristics in a kindred with early-onset Alzheimer's disease and their linkage to a G-to-T change at position 2149 of the amyloid precursor protein gene. Neurology 1994; 44:105-111
29. Felsenstein KM, Hunihan LW, Roberts SB: Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation. Nature Genet 1994; 6:251-256
30. Grabowski TJ, Cho HS, Vonsattel JPG, et al: Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 2001; 49:697-705
31. Greenberg SM, Shin Y, Grabowski TJ, et al: Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. Neurology 2003; 60:1020-1022
32. Haass C, Lemere CA, Capell A, et al: The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1995; 1:1291-1296
33. Hol EM, van Dijk R, Gerez L, et al: Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, pathology. J Biol Chem 2003; 278:39637-39643
34. Hendriks L, van Duijn CM, Cras P, et al: Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992; 1:218-221
35. Karlinsky H, Vaula G, Haines JL, et al: Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the beta-amyloid precursor protein gene. Neurology 1992; 42:1445-1453
36. Levy E, Carman MD, Fernandez-Madrid IJ, et al: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990; 248:1124-1126
37. Maruyama K, Tomita T, Shinozaki K, et al: Familial Alzheimer's disease-linked mutations at val717 of amyloid precursor protein are specific for the increased secretion of A-beta-42(43). Biochem Biophys Res Commun 1996; 227:730-735
38. Mullan M, Crawford F, Axelman K, et al: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992; 1:345-347
39. Murrell J, Farlow M, Ghetti B, et al: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991; 254:97-99
40. Naruse S, Igarashi S, Kobayashi H, et al: Mis-sense mutation val-to-ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease [Letter]. Lancet 1991; 337: 978-979
41. Rossi G, Giaccone G, Maletta R, et al: A family with Alzheimer disease and strokes associated with the A713T mutation of the APP gene. Neurology 2004; 63:910-912
42. Tanzi RE, Vaula G, Romano DM, et al: Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 1992; 51:273-282
43. Van Broeckhoven C, Haan J, Bakker E, et al: Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis [Dutch]. Science 1990; 248:1120-1122
44. Zeldenrust SR, Murrell J, Farlow M, et al: RFLP analysis for APP 717 mutations associated with Alzheimer's disease. J Med Genet 1993; 30:476-478
45. Saunders AM, Schmader K, Breitner JC, et al: Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993; 342:710-711
46. Alzheimer's Disease Collaborative Group: The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995; 11:219-222
47. Ataka S, Tomiyama T, Takuma H, et al: A novel presenilin-1 mutation (leu85pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol 2004; 61:1773-1776
48. Athan ES, Williamson J, Ciappa A, et al: A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 2001; 286:2257-2263
49. Crook R, Verkkoniemi A, Perez-Tur J, et al: A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998; 4:452-455
50. Cruts M, Van Broeckhoven C: Presenilin mutations in Alzheimer's disease. Hum Mutat 1998; 11:183-190
51. Matsubara-Tsutsui M, Yasuda M, Yamagata H, et al: Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am J Med Genet 2002; 114:292-298
52. O'Riordan S, McMonagle P, Janssen JC, et al: Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59:1108-1110
53. Alzheimer's Disease Collaborative Group: The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 1995; 11:219-222
54. Binetti G, Signorini S, Squitti R, et al: Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol 2003; 54:832-836
55. Ezquerra M, Lleo A, Castellvi M, et al: A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 2003; 60:1149-1151
56. Finckh U, Muller-Thomsen T, Mann U, et al: High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 2000; 66:110-117
57. Lleo A, Blesa R, Gendre J, et al: A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. Neurology 2001; 57:1926-1928
58. Rogaev EI, Sherrington R, Rogaeva EA, et al: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376:775-778
59. Tomita T, Maruyama K, Saido TC, et al: The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A 1997; 94:2025-2030
60. Arima K, Kowalska A, Hasegawa M, et al: Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology 2000; 54:1787-1795
61. Baker M, Litvan I, Houlden H, et al: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8:711-715
62. Clark LN, Poorkaj P, Wszolek Z, et al: Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 1998; 95:13103-13107
63. Delisle MB, Murrell JR, Richardson R, et al: A mutation at codon 279 (N279K) in exon 10 of the tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol 1999; 98:62-77
64. Goedert M, Crowther RA, Spillantini MG: Tau mutations cause frontotemporal dementias. Neuron 1998; 21:955-958
65. Hayashi S, Toyoshima Y, Hasegawa M, et al: Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol 2002; 51:525-530
66. Heutink P, Stevens M, Rizzu P, et al: Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol 1997; 41:150-159
67. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al: Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998; 282:1914-1917
68. Hutton M: Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001; 56(suppl 4):S21-S25
69. Kobayashi T, Ota S, Tanaka K, et al: A novej L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol 2003; 53:133-137
70. Lippa CF, Zhukareva V, Kawarai T, et al: Frontotemporal dementia with novel tau pathology and a glu342val tau mutation. Ann Neurol 2000; 48:850-858
71. Miyamoto K, Kowalska A, Hasegawa M, et al: Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene. Ann Neurol 2001; 50:117-120
72. Murrell JR, Spillantini MG, Zolo P, et al: Tau gene mutation G389R causes a tauopathy with abundant Pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol 1999; 58:1207-1226
73. Neumann M, Schulz-Schaeffer W, Crowther RA, et al: Pick's disease associated with the novel tau gene mutation K369I. Ann Neurol 2001; 50:503-513
74. Nicholl DJ, Greenstone MA, Clarke CE, et al: An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol 2003; 54:682-686
75. Oliva R, Pastor P: Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy [Letter]. Ann Neurol 2004; 55:448-449
76. Pastor P, Pastor E, Carnero C, et al: Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene. Ann Neurol 2001; 49:263-267
77. Pickering-Brown S, Baker M, Yen SH, et al: Pick's disease is associated with mutations in the tau gene. Ann Neurol 2000; 48:859-867
78. Poorkaj P, Grossman M, Steinbart E, et al: Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 2001; 58:383-387
79. Poorkaj P, Muma NA, Zhukareva V, et al: An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 2002; 52:511-516
80. Rademakers R, Cruts M, van Broeckhoven C: The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 2004; 24:277-295
81. Spillantini MG, Murrell JR, Goedert M, et al: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998; 95:7737-7741
82. van Swieten JC, Stevens M, Rosso SM, et al: Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol 1999; 46:617-626
83. Wszolek ZK, Uitti RJ, Hutton M: A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration [Letter]. Neurology 2000; 54:2028-2030
84. Zarranz JJ, Ferrer I, Lezcano E, et al: A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology 2005; 64:1578-1585
85. Zhukareva V, Mann D, Pickering-Brown S, et al: Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 2002; 51:730-739
86. Jorm AF, O'Brien J: The epidemiology of vascular dementia. An overview and commentary, in Cerebrovascular Disease, Cognitive Impairment and Dementia, 2nd ed. Edited by O'Brien J, Ames D, Gustafson L, et al. London, Martin Dunitz, 2004, pp 95-100
87. Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-260
88. Roman GC: Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res 2004; 26:454-458
89. Sachdev P: Vascular cognitive disorder. Int J Geriatr Psychiatry 1999; 14:402-403
90. Mendez MF, Cummings JL: Dementia, a Clinical Approach.; Philadelphia, Butterworth-Heinemann (Elsevier), 2003, pp 142-146
91. Sourander P, Walinder J: Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol (Berl) 1977; 39:247-254
92. Markus HS, Martin RJ, Simpson MA: Diagnostic strategies in CADASIL. Neurology 2002; 59:1134-1138
93. Khachaturian ZS: Progress of research on Alzheimer's disease. Research opportunities for behavioral scientists. Am Psychol 1985; 40:1251-1255
94. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872
95. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164-173
96. Ohtake H, Limprasert P, Fan Y, et al: Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004; 63:805-811
97. Steffens DC, Otey E, Alexopoulos GS, et al: Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry 2006; 63:130-138
98. Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308
99. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194
100. Finckh U, Kuschel C, Anagnostouli M, et al: Novel mutations and repeated findings of mutations in familial Alzheimer disease. Neurogenetics 2005; 2:85-89
101. Rosso SM, Donker Kaat L, Baks T, et al: Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126:2016-2022